English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 855736      Online Users : 1364
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/7952


    Title: HOXC6 overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma
    Authors: Win, KT;Li, CF
    Contributors: National Institute of Cancer Research
    Abstract: Background: Though the advances in diagnostic imaging and treatment modalities have achieved better locoregional control of nasopharyngeal carcinoma (NPC), it appears less satisfactory in fi nal treatment outcomes. Through data mining from public domain, homeobox C6 (HOXC6) was fi rst identifi ed as a differentially upregulated gene associated with regulation of transcription from RNA polymerase II promoter in the transcriptome of NPCs. HOXC6 belongs to a member of the homeobox family, deregulated expression of which has been observed in many tumor types including leukemia, breast, lung, and prostate cancer. Since its signifi cant has not been systematically investigated in NPC, we therefore explored the signifi cance of HOXC6 immunoexpression status and its association with cell proliferation index Ki-67 in a large cohort of NPC patients.Design: HOXC6 and Ki-67 immunohistochemistry was retrospectively performed and analyzed using H-score method for biopsy specimens from 124 NPC patients who received standard treatment without distant metastasis at initial diagnosis. Those cases with H-score larger than the median value were defi ned as HOXC6 overexpression. The results were correlated with the clinicopathological variables, disease-specifi c survival (DSS) and metastasis-free survival (MeFS).Results: HOXC6 overexpression was signifi cantly positively associated with Ki-67 expression, and signifi cantly associated with increments of tumor stage (p=0.024), advanced nodal status (p<0.001) and American Joint Committee on Cancer (AJCC) stage (p=0.002). Its overexpression also correlated with worse prognosis in terms of DSS (p=0.0008), MeFS (p=0.0047) univariately. In multivariate comparisons, HOXC6 overexpression still remained prognostically independent to portend worse DSS (p=0.015, hazard ratio=1.988) and MeFS (p=0.036, hazard ratio=1.899), together with advanced AJCC stages III-IV (p=0.024, DSS; p=0.043, MeFS).Conclusions: HOXC6 expression is upregulated in a subset of NPCs and its increased immunoexpression signifi cantly correlated with advanced stages and tumor aggressiveness, justifying the potentiality of HOXC6 as a prognostic biomarker and a novel therapeutic target of NPC.
    Date: 2014-02
    Relation: Laboratory Investigation. 2014 Feb;94(S1):331A.
    Link to: http://dx.doi.org/10.1038/labinvest.2014.25
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0023-6837&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000331155801583
    Appears in Collections:[Others] Conference Papers/Meeting Abstract

    Files in This Item:

    File Description SizeFormat
    ISI000331155801583.pdf137KbAdobe PDF566View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback